RT Journal Article
SR Electronic
T1 Novel Epidermal Growth Factor Receptor Inhibitor Attenuates Angiotensin II–Induced Kidney Fibrosis
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 32
OP 42
DO 10.1124/jpet.115.228080
VO 356
IS 1
A1 Qian, Yuanyuan
A1 Peng, Kesong
A1 Qiu, Chenyu
A1 Skibba, Melissa
A1 Huang, Yi
A1 Xu, Zheng
A1 Zhang, Yali
A1 Hu, Jie
A1 Liang, Dandan
A1 Zou, Chunpeng
A1 Wang, Yi
A1 Liang, Guang
YR 2016
UL http://jpet.aspetjournals.org/content/356/1/32.abstract
AB Chronic activation of renin-angiotensin system (RAS) greatly contributes to renal fibrosis and accelerates the progression of chronic kidney disease; however, the underlying molecular mechanism is poorly understood. Angiotensin II (Ang II), the central component of RAS, is a key regulator of renal fibrogenic destruction. Here we show that epidermal growth factor receptor (EGFR) plays an important role in Ang II–induced renal fibrosis. Inhibition of EGFR activation by novel small molecules or by short hairpin RNA knockdown in Ang II–treated SV40 mesangial cells in vitro suppresses protein kinase B and extracellular signal-related kinase signaling pathways and transforming growth factor-β/Sma- and Mad-related protein activation, and abolishes the accumulation of fibrotic markers such as connective tissue growth factor, collagen IV. The transactivation of EGFR by Ang II in SV40 cells depends on the phosphorylation of proto-oncogene tyrosine-protein kinase Src (c-Src) kinase. Further validation in vivo demonstrates that EGFR small molecule inhibitor successfully attenuates renal fibrosis and kidney dysfunction in a mouse model induced by Ang II infusion. These findings indicate a crucial role of EGFR in Ang II–dependent renal deterioration, and reveal EGFR inhibition as a new therapeutic strategy for preventing progression of chronic renal diseases.